Global Future Council on Antimicrobial Resistance

Global Future Council on Antimicrobial Resistance

Antimicrobial resistance (AMR) is already a leading cause of death globally, higher than HIV/AIDS or malaria. What novel approaches are needed to accelerate effective action on AMR?

Members

Chief Executive Officer, Dubai Health

Amer Ahmad Sharif

Antimicrobial Resistance Control and One Health Unit Lead, Africa Centres for Disease Control and Prevention (Africa CDC)

Visiting Senior Fellow, LSE Health, London School of Economics (LSE)

Michael Anderson

Chief, External Affairs, CARB-X

Damiano de Felice

South African Research Chair in Antibiotic Resistance and One Health; Professor in Pharmaceutical Sciences, University of KwaZulu-Natal

Director, Global Public Policy, MSD

Principal, Antimicrobial Resistance, IQVIA

Professor of Infectious Diseases; Director, Fleming Initiative, Imperial College London

Head, Policy, Infectious Disease, Wellcome Trust

Director, Investment Stewardship, Asset Management, Legal & General Group

Maria Larsson Ortino

Public Affairs Director, Novo Nordisk Foundation

Alexandra Lichtenstein Kaarsen

Policy Fellow, Center for Global Development

Anthony McDonnell

Country Director, Nigeria, PharmAccess Foundation

Coordinator, Antimicrobial Resistance and Infection Prevention and Control Programme, Nigeria Centre for Disease Control (CDC)

Director, International Policy, AMR Action Fund

Professor, School of Public Health, Peking University

Editor-in-Chief, AMR.Solutions

Senior Health Specialist, World Bank Group

Naomi Rupasinghe

Deputy Director, Gates Foundation

Padmini Srikantiah

Chair, Friends of the Global Fight Against AIDS, Tuberculosis and Malaria

Jeffrey L. Sturchio

関連レポート

Targeted Action and Financing the Fight Against Antimicrobial Resistance in Asia

Antimicrobial resistance, superbugs, antibiotics, animal farming, climate risk

報告書 — 2025年5月5日

もっと読む関連するすべてのコンテンツ

薬剤耐性が、血液がん治療のサイレントリスクでなくなる日

がん治療は今、新たなイノベーションの時代を迎えています。免疫療法、分子標的治療、細胞療法の進歩により、患者の治療アウトカムは劇的に改善しつつあります。ただし、これらの画期的な治療法のすべては、抗微生物薬という脆弱な基盤の上に成り立っています。

How antimicrobial resistance is risking blood cancer treatment

Cancer care has entered a new era of innovation. Advances in immunotherapy, targeted treatments and cellular therapies are transforming patient outcomes. Yet all these breakthroughs rest ...

関連ビデオ

Davos AM24 - Facing a World without Antibiotics - English

2024年01月16日

Superbugs caused by antibiotic resistance are a rising threat. Here's how we can beat them

2023年11月20日